Al-Kabban Anmar, Al-Kabban Fadi M, Obaid Ola
Gastroenterology, North Zealand Hospital, Hillerød, DNK.
General Surgery, King's College Hospital NHS Foundation Trust, London, GBR.
Cureus. 2025 Jul 15;17(7):e88043. doi: 10.7759/cureus.88043. eCollection 2025 Jul.
Endoscopic retrograde cholangiopancreatography (ERCP) is a critical therapeutic intervention for hepatobiliary and pancreatic disorders, yet it carries significant morbidity and mortality risks due to the complications that may occur due to changes in the microbiota of the hepatobiliary system. Achieving the best patient results requires mastery of current complications, their risk factors, and proven management methods. This study aims to systematically review the incidence, risk factors, microbial patterns, and management strategies of post-ERCP complications in contemporary practice. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Multiple databases were searched for studies published between 2004 and 2025 reporting post-ERCP complications. Studies were assessed using the Mixed Methods Appraisal Tool (MMAT). Data extraction focused on incidence, complication rates, risk factors, microbial patterns, and management approaches. Ten studies (n = 14,581 procedures) were included, comprising retrospective cohorts, prospective registries, and surveillance studies. Overall complication rates ranged from 9.4% to 15.9%, with procedure-related mortality of 0.26% to 1.0%. Post-ERCP pancreatitis (PEP) was the most common complication (3.8-17.2%), followed by complications due to infection, including cholangitis (2.4-9.7%) and bloodstream infections (2.24/100 procedures). Microbial studies demonstrated high rates of bile contamination (>86%) with concerning antibiotic resistance patterns, particularly among and . The most identified pathogens included , which account for 29% of bloodstream infections, and , responsible for 22% of bloodstream infections. Key risk factors included advanced age, previous ERCP history, stent placement, and hilar obstruction. Imaging studies revealed intra-abdominal collections (51.2%) as the most frequent CT-detectable complication. ERCP-related complications remain significant in contemporary practice, with infectious complications showing evolving microbial resistance patterns. Risk stratification based on identified factors can guide patient selection and prophylaxis protocols. Standardized surveillance and early recognition protocols are essential for optimal outcomes.
内镜逆行胰胆管造影术(ERCP)是治疗肝胆和胰腺疾病的关键治疗手段,但由于肝胆系统微生物群变化可能引发并发症,该手术存在显著的发病和死亡风险。要取得最佳治疗效果,需要掌握当前并发症、其危险因素及已证实的管理方法。本研究旨在系统回顾当代实践中ERCP术后并发症的发生率、危险因素、微生物模式及管理策略。按照系统评价和Meta分析的首选报告项目(PRISMA)指南进行系统评价。在多个数据库中检索2004年至2025年发表的报告ERCP术后并发症的研究。使用混合方法评估工具(MMAT)对研究进行评估。数据提取集中在发生率、并发症发生率、危险因素、微生物模式及管理方法。纳入了10项研究(n = 14,581例手术),包括回顾性队列研究、前瞻性登记研究和监测研究。总体并发症发生率在9.4%至15.9%之间,手术相关死亡率为0.26%至1.0%。ERCP术后胰腺炎(PEP)是最常见的并发症(3.8 - 17.2%),其次是感染性并发症,包括胆管炎(2.4 - 9.7%)和血流感染(2.24/100例手术)。微生物研究表明胆汁污染率很高(>86%),且存在令人担忧的抗生素耐药模式,尤其是在……和……中。最常见的病原体包括……,占血流感染的29%,以及……,占血流感染的22%。关键危险因素包括高龄、既往ERCP史、支架置入和肝门梗阻。影像学研究显示腹腔内积液(51.2%)是CT最常检测到的并发症。在当代实践中,ERCP相关并发症仍然很严重,感染性并发症呈现出不断演变的微生物耐药模式。基于已确定因素的风险分层可指导患者选择和预防方案。标准化监测和早期识别方案对于实现最佳治疗效果至关重要。